Paraskevi Apostolou

发表

Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.

Jane E. Carpenter, Kristen S Purrington, Victoria L. Cafourek, 2014, Carcinogenesis.

Breast Cancer Susceptibility Genes

F. Fostira, A. Vratimos, P. Apostolou, 2015 .

ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

James M. Hodge, E. Burnside, Y. Kamatani, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

CanVaS: Documenting the genetic variation spectrum of Greek cancer patients

F. Fostira, D. Yannoukakos, I. Vlachos, 2021, Human mutation.

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

Olufunmilayo I. Olopade, Mads Thomassen, Dieter Niederacher, 2016, Breast Cancer Research.

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

Nicholas A. Sinnott-Armstrong, Richard C. Sallari, S. Cross, 2016, Nature Genetics.

Breast cancer risk variants at 6 q 25 display different phenotype associations and regulate ESR 1 , RMND 1 and CCDC 170

Wei Zheng, Mads Thomassen, Nicholas A. Sinnott-Armstrong, 2016 .

Hereditary Breast Cancer: The Era of New Susceptibility Genes

Florentia Fostira, F. Fostira, Paraskevi Apostolou, 2013, BioMed research international.

Molecular profile and clinical features of patients with gliomas using a broad targeted next generation-sequencing panel.

F. Fostira, K. Papadopoulou, G. Fountzilas, 2022, Oncology letters.

Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece

F. Fostira, D. Yannoukakos, C. Papadimitriou, 2018, Journal of Human Genetics.

Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer

F. Fostira, D. Yannoukakos, D. Mauri, 2018, Breast Cancer Research and Treatment.

PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk

F. Fostira, D. Yannoukakos, C. Papadimitriou, 2019, Journal of Human Genetics.

CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases.

F. Fostira, D. Yannoukakos, G. Voutsinas, 2015, Cancer genetics.

Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system

A. Papavassiliou, F. Fostira, D. Yannoukakos, 2019, Human mutation.

Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients

F. Fostira, D. Yannoukakos, G. Fountzilas, 2018, Journal of Human Genetics.

Epidemiological and clinicopathological characteristics of BRCA-positive and BRCA-negative breast cancer patients in Greece.

F. Fostira, D. Yannoukakos, C. Loghis, 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries

F. Fostira, K. Papadopoulou, G. Fountzilas, 2021, Breast Cancer.

Extending the clinical phenotype associated with biallelic NTHL1 germline mutations

F. Fostira, D. Yannoukakos, E. Saloustros, 2018, Clinical genetics.

Physicians’ experience, practice and education, on genetic testing and genetic counseling: a nationwide survey study in Greece

F. Fostira, E. Fountzilas, E. Saloustros, 2022, Familial Cancer.

CHEK2 Pathogenic Variants in Greek Breast Cancer Patients: Evidence for Strong Associations with Estrogen Receptor Positivity, Overuse of Risk-Reducing Procedures and Population Founder Effects

F. Fostira, C. Papadimitriou, E. Fountzilas, 2021, Cancers.

Prevalence and founder effect of the BRCA1 p.(Val1833Met) variant in the Greek population, with further evidence for pathogenicity and risk modification.

F. Fostira, D. Yannoukakos, D. Loutradis, 2019, Cancer genetics.

Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.

F. Fostira, D. Yannoukakos, C. Papadimitriou, 2019, Clinical breast cancer.

BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects

D. Mavroudis, V. Georgoulias, F. Fostira, 2020, International journal of cancer.

Early non-invasive detection of fetal Y chromosome sequences in maternal plasma using multiplex PCR.

E. Kanavakis, C. Vrettou, A. Antsaklis, 2012, European journal of obstetrics, gynecology, and reproductive biology.

ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics

V. Pappa, A. Daraki, K. Manola, 2018, Leukemia & lymphoma.

Hereditary Breast Cancer: The Era of New Susceptibility Genes

F. Fostira, Paraskevi Apostolou, 2013, BioMed research international.

Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients

F. Fostira, D. Yannoukakos, G. Fountzilas, 2018, Journal of Human Genetics.

One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene

F. Fostira, D. Yannoukakos, C. Papadimitriou, 2019, Journal of Medical Genetics.

Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer

F. Fostira, D. Yannoukakos, D. Mauri, 2018, Breast Cancer Research and Treatment.

PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk

F. Fostira, D. Yannoukakos, C. Papadimitriou, 2019, Journal of Human Genetics.

Human Mutation

Colby T. Ford, Lipika R. Pal, Meng Wang, 2019 .

Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation

F. Fostira, D. Yannoukakos, C. Papadimitriou, 2017, Clinical genetics.

The fate of BRCA1-related germline mutations in triple-negative breast tumors.

F. Fostira, D. Yannoukakos, H. Gogas, 2017, American journal of cancer research.